☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
WM
BeiGene's Brukinsa (zanubrutinib) Receives the NMPA's Approval for Relapsed or Refractory Waldenström's Macroglobulinemia
June 21, 2021
Load more...
Back to Home